Global Neuraminidase Inhibitor Market Growth 2021-2026
According to this latest study, the 2021 growth of Neuraminidase Inhibitor will have significant change from previous year. By the most conservative estimates of global Neuraminidase Inhibitor market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Neuraminidase Inhibitor market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuraminidase Inhibitor market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospital Pharmacies
Drug Stores
Retail Stores
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuraminidase Inhibitor Consumption 2016-2026
2.1.2 Neuraminidase Inhibitor Consumption CAGR by Region
2.2 Neuraminidase Inhibitor Segment by Type
2.2.1 Zanamivir
2.2.2 Oseltamivir
2.2.3 Peramivir
2.2.4 Laninamivir
2.3 Neuraminidase Inhibitor Sales by Type
2.3.1 Global Neuraminidase Inhibitor Sales Market Share by Type (2016-2021)
2.3.2 Global Neuraminidase Inhibitor Revenue and Market Share by Type (2016-2021)
2.3.3 Global Neuraminidase Inhibitor Sale Price by Type (2016-2021)
2.4 Neuraminidase Inhibitor Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Drug Stores
2.4.3 Retail Stores
2.4.4 Others
2.5 Neuraminidase Inhibitor Sales by Application
2.5.1 Global Neuraminidase Inhibitor Sale Market Share by Application (2016-2021)
2.5.2 Global Neuraminidase Inhibitor Revenue and Market Share by Application (2016-2021)
2.5.3 Global Neuraminidase Inhibitor Sale Price by Application (2016-2021)
3 Global Neuraminidase Inhibitor by Company
3.1 Global Neuraminidase Inhibitor Sales Market Share by Company
3.1.1 Global Neuraminidase Inhibitor Sales by Company (2019-2021)
3.1.2 Global Neuraminidase Inhibitor Sales Market Share by Company (2019-2021)
3.2 Global Neuraminidase Inhibitor Revenue Market Share by Company
3.2.1 Global Neuraminidase Inhibitor Revenue by Company (2019-2021)
3.2.2 Global Neuraminidase Inhibitor Revenue Market Share by Company (2019-2021)
3.3 Global Neuraminidase Inhibitor Sale Price by Company
3.4 Global Manufacturers Neuraminidase Inhibitor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuraminidase Inhibitor Product Location Distribution
3.4.2 Players Neuraminidase Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Neuraminidase Inhibitor by Region
4.1 Global Neuraminidase Inhibitor by Region
4.1.1 Global Neuraminidase Inhibitor Sales by Region
4.1.2 Global Neuraminidase Inhibitor Revenue by Region
4.2 Americas Neuraminidase Inhibitor Sales Growth
4.3 APAC Neuraminidase Inhibitor Sales Growth
4.4 Europe Neuraminidase Inhibitor Sales Growth
4.5 Middle East & Africa Neuraminidase Inhibitor Sales Growth
5 Americas
5.1 Americas Neuraminidase Inhibitor Sales by Country
5.1.1 Americas Neuraminidase Inhibitor Sales by Country (2016-2021)
5.1.2 Americas Neuraminidase Inhibitor Revenue by Country (2016-2021)
5.2 Americas Neuraminidase Inhibitor Sales by Type
5.3 Americas Neuraminidase Inhibitor Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuraminidase Inhibitor Sales by Region
6.1.1 APAC Neuraminidase Inhibitor Sales by Region (2016-2021)
6.1.2 APAC Neuraminidase Inhibitor Revenue by Region (2016-2021)
6.2 APAC Neuraminidase Inhibitor Sales by Type
6.3 APAC Neuraminidase Inhibitor Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neuraminidase Inhibitor by Country
7.1.1 Europe Neuraminidase Inhibitor Sales by Country (2016-2021)
7.1.2 Europe Neuraminidase Inhibitor Revenue by Country (2016-2021)
7.2 Europe Neuraminidase Inhibitor Sales by Type
7.3 Europe Neuraminidase Inhibitor Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neuraminidase Inhibitor by Country
8.1.1 Middle East & Africa Neuraminidase Inhibitor Sales by Country (2016-2021)
8.1.2 Middle East & Africa Neuraminidase Inhibitor Revenue by Country (2016-2021)
8.2 Middle East & Africa Neuraminidase Inhibitor Sales by Type
8.3 Middle East & Africa Neuraminidase Inhibitor Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Neuraminidase Inhibitor Distributors
10.3 Neuraminidase Inhibitor Customer
11 Global Neuraminidase Inhibitor Market Forecast
11.1 Global Neuraminidase Inhibitor Forecast by Region
11.1.1 Global Neuraminidase Inhibitor Forecast by Regions (2021-2026)
11.2.2 Global Neuraminidase Inhibitor Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global Neuraminidase Inhibitor Forecast by Type
11.7 Global Neuraminidase Inhibitor Forecast by Application
12 Key Players Analysis
12.1 GlaxoSmithKline
12.1.1 GlaxoSmithKline Company Information
12.1.2 GlaxoSmithKline Neuraminidase Inhibitor Product Offered
12.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 GlaxoSmithKline Main Business Overview
12.1.5 GlaxoSmithKline Latest Developments
12.2 Gilead Sciences
12.2.1 Gilead Sciences Company Information
12.2.2 Gilead Sciences Neuraminidase Inhibitor Product Offered
12.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Gilead Sciences Main Business Overview
12.2.5 Gilead Sciences Latest Developments
12.3 F. Hoffman-La Roche
12.3.1 F. Hoffman-La Roche Company Information
12.3.2 F. Hoffman-La Roche Neuraminidase Inhibitor Product Offered
12.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 F. Hoffman-La Roche Main Business Overview
12.3.5 F. Hoffman-La Roche Latest Developments
12.4 BioCryst
12.4.1 BioCryst Company Information
12.4.2 BioCryst Neuraminidase Inhibitor Product Offered
12.4.3 BioCryst Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 BioCryst Main Business Overview
12.4.5 BioCryst Latest Developments
12.5 Daiichi Sankyo
12.5.1 Daiichi Sankyo Company Information
12.5.2 Daiichi Sankyo Neuraminidase Inhibitor Product Offered
12.5.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Daiichi Sankyo Main Business Overview
12.5.5 Daiichi Sankyo Latest Developments
...
13 Research Findings and Conclusion
List of Tables
Table 1. Neuraminidase Inhibitor Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Zanamivir
Table 3. Major Players of Oseltamivir
Table 4. Major Players of Peramivir
Table 5. Major Players of Laninamivir
Table 6. Global Neuraminidase Inhibitor Sales by Type (2016-2021) & (K Units)
Table 7. Global Neuraminidase Inhibitor Sales Market Share by Type (2016-2021)
Table 8. Global Neuraminidase Inhibitor Revenue by Type (2016-2021) & ($ million)
Table 9. Global Neuraminidase Inhibitor Revenue Market Share by Type (2016-2021)
Table 10. Global Neuraminidase Inhibitor Sale Price by Type (2016-2021)
Table 11. Global Neuraminidase Inhibitor Sales by Application (2016-2021) & (K Units)
Table 12. Global Neuraminidase Inhibitor Sales Market Share by Application (2016-2021)
Table 13. Global Neuraminidase Inhibitor Value by Application (2016-2021)
Table 14. Global Neuraminidase Inhibitor Revenue Market Share by Application (2016-2021)
Table 15. Global Neuraminidase Inhibitor Sale Price by Application (2016-2021)
Table 16. Global Neuraminidase Inhibitor Sales by Company (2019-2021) & (K Units)
Table 17. Global Neuraminidase Inhibitor Sales Market Share by Company (2019-2021)
Table 18. Global Neuraminidase Inhibitor Revenue by Company (2019-2021) ($ Millions)
Table 19. Global Neuraminidase Inhibitor Revenue Market Share by Company (2019-2021)
Table 20. Global Neuraminidase Inhibitor Sale Price by Company (2019-2021)
Table 21. Key Manufacturers Neuraminidase Inhibitor Producing Area Distribution and Sales Area
Table 22. Players Neuraminidase Inhibitor Products Offered
Table 23. Neuraminidase Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Neuraminidase Inhibitor Sales by Region (2016-2021) (K Units)
Table 27. Global Neuraminidase Inhibitor Sales Market Share by Region (2016-2021)
Table 28. Global Neuraminidase Inhibitor Revenue by Region (2016-2021) & ($ Millions)
Table 29. Global Neuraminidase Inhibitor Revenue Market Share by Region (2016-2021)
Table 30. Americas Neuraminidase Inhibitor Sales by Country (2016-2021) & (K Units)
Table 31. Americas Neuraminidase Inhibitor Sales Market Share by Country (2016-2021)
Table 32. Americas Neuraminidase Inhibitor Revenue by Country (2016-2021) & ($ Millions)
Table 33. Americas Neuraminidase Inhibitor Revenue Market Share by Country (2016-2021)
Table 34. Americas Neuraminidase Inhibitor Sales by Type (2016-2021) & (K Units)
Table 35. Americas Neuraminidase Inhibitor Sales Market Share by Type (2016-2021)
Table 36. Americas Neuraminidase Inhibitor Sales by Application (2016-2021) & (K Units)
Table 37. Americas Neuraminidase Inhibitor Sales Market Share by Application (2016-2021)
Table 38. APAC Neuraminidase Inhibitor Sales by Region (2016-2021) & (K Units)
Table 39. APAC Neuraminidase Inhibitor Sales Market Share by Region (2016-2021)
Table 40. APAC Neuraminidase Inhibitor Revenue by Region (2016-2021) & ($ Millions)
Table 41. APAC Neuraminidase Inhibitor Revenue Market Share by Region (2016-2021)
Table 42. APAC Neuraminidase Inhibitor Sales by Type (2016-2021) & (K Units)
Table 43. APAC Neuraminidase Inhibitor Sales Market Share by Type (2016-2021)
Table 44. APAC Neuraminidase Inhibitor Sales by Application (2016-2021) & (K Units)
Table 45. APAC Neuraminidase Inhibitor Sales Market Share by Application (2016-2021)
Table 46. Europe Neuraminidase Inhibitor Sales by Country (2016-2021) & (K Units)
Table 47. Europe Neuraminidase Inhibitor Sales Market Share by Country (2016-2021)
Table 48. Europe Neuraminidase Inhibitor Revenue by Country (2016-2021) & ($ Millions)
Table 49. Europe Neuraminidase Inhibitor Revenue Market Share by Country (2016-2021)
Table 50. Europe Neuraminidase Inhibitor Sales by Type (2016-2021) & (K Units)
Table 51. Europe Neuraminidase Inhibitor Sales Market Share by Type (2016-2021)
Table 52. Europe Neuraminidase Inhibitor Sales by Application (2016-2021) & (K Units)
Table 53. Europe Neuraminidase Inhibitor Sales Market Share by Application (2016-2021)
Table 54. Middle East & Africa Neuraminidase Inhibitor Sales by Country (2016-2021) & (K Units)
Table 55. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Country (2016-2021)
Table 56. Middle East & Africa Neuraminidase Inhibitor Revenue by Country (2016-2021) & ($ Millions)
Table 57. Middle East & Africa Neuraminidase Inhibitor Revenue Market Share by Country (2016-2021)
Table 58. Middle East & Africa Neuraminidase Inhibitor Sales by Type (2016-2021) & (K Units)
Table 59. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Type (2016-2021)
Table 60. Middle East & Africa Neuraminidase Inhibitor Sales by Application (2016-2021) & (K Units)
Table 61. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Application (2016-2021)
Table 62. Key and Potential Regions of Neuraminidase Inhibitor
Table 63. Key Application and Potential Industries of Neuraminidase Inhibitor
Table 64. Key Challenges of Neuraminidase Inhibitor
Table 65. Key Trends of Neuraminidase Inhibitor
Table 66. Neuraminidase Inhibitor Distributors List
Table 67. Neuraminidase Inhibitor Customer List
Table 68. Global Neuraminidase Inhibitor Sales Forecast by Region (2021-2026) & (K Units)
Table 69. Global Neuraminidase Inhibitor Consumption Market Forecast by Region
Table 70. Global Neuraminidase Inhibitor Revenue Forecast by Region (2021-2026) & ($ millions)
Table 71. Global Neuraminidase Inhibitor Revenue Market Share Forecast by Region (2021-2026)
Table 72. Americas Neuraminidase Inhibitor Sales Forecast by Country (2021-2026) & (K Units)
Table 73. Americas Neuraminidase Inhibitor Revenue Forecast by Country (2021-2026) & ($ millions)
Table 74. APAC Neuraminidase Inhibitor Sales Forecast by Region (2021-2026) & (K Units)
Table 75. APAC Neuraminidase Inhibitor Revenue Forecast by Region (2021-2026) & ($ millions)
Table 76. Europe Neuraminidase Inhibitor Sales Forecast by Country (2021-2026) & (K Units)
Table 77. Europe Neuraminidase Inhibitor Revenue Forecast by Country (2021-2026) & ($ millions)
Table 78. Middle East & Africa Neuraminidase Inhibitor Sales Forecast by Country (2021-2026) & (K Units)
Table 79. Middle East & Africa Neuraminidase Inhibitor Revenue Forecast by Country (2021-2026) & ($ millions)
Table 80. Global Neuraminidase Inhibitor Sales Forecast by Type (2021-2026) & (K Units)
Table 81. Global Neuraminidase Inhibitor Sales Market Share Forecast by Type (2021-2026)
Table 82. Global Neuraminidase Inhibitor Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 83. Global Neuraminidase Inhibitor Revenue Market Share Forecast by Type (2021-2026)
Table 84. Global Neuraminidase Inhibitor Sales Forecast by Application (2021-2026) & (K Units)
Table 85. Global Neuraminidase Inhibitor Sales Market Share Forecast by Application (2021-2026)
Table 86. Global Neuraminidase Inhibitor Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 87. Global Neuraminidase Inhibitor Revenue Market Share Forecast by Application (2021-2026)
Table 88. GlaxoSmithKline Basic Information, Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 89. GlaxoSmithKline Neuraminidase Inhibitor Product Offered
Table 90. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 91. GlaxoSmithKline Main Business
Table 92. GlaxoSmithKline Latest Developments
Table 93. Gilead Sciences Basic Information, Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 94. Gilead Sciences Neuraminidase Inhibitor Product Offered
Table 95. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 96. Gilead Sciences Main Business
Table 97. Gilead Sciences Latest Developments
Table 98. F. Hoffman-La Roche Basic Information, Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 99. F. Hoffman-La Roche Neuraminidase Inhibitor Product Offered
Table 100. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 101. F. Hoffman-La Roche Main Business
Table 102. F. Hoffman-La Roche Latest Developments
Table 103. BioCryst Basic Information, Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 104. BioCryst Neuraminidase Inhibitor Product Offered
Table 105. BioCryst Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 106. BioCryst Main Business
Table 107. BioCryst Latest Developments
Table 108. Daiichi Sankyo Basic Information, Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 109. Daiichi Sankyo Neuraminidase Inhibitor Product Offered
Table 110. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 111. Daiichi Sankyo Main Business
Table 112. Daiichi Sankyo Latest Developments
List of Figures
Figure 1. Picture of Neuraminidase Inhibitor
Figure 2. Neuraminidase Inhibitor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neuraminidase Inhibitor Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Neuraminidase Inhibitor Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Neuraminidase Inhibitor Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Zanamivir
Figure 10. Product Picture of Oseltamivir
Figure 11. Product Picture of Peramivir
Figure 12. Product Picture of Laninamivir
Figure 13. Global Neuraminidase Inhibitor Sales Market Share by Type in 2020
Figure 14. Global Neuraminidase Inhibitor Revenue Market Share by Type (2016-2021)
Figure 15. Neuraminidase Inhibitor Consumed in Hospital Pharmacies
Figure 16. Global Neuraminidase Inhibitor Market: Hospital Pharmacies (2016-2021) & (K Units)
Figure 17. Neuraminidase Inhibitor Consumed in Drug Stores
Figure 18. Global Neuraminidase Inhibitor Market: Drug Stores (2016-2021) & (K Units)
Figure 19. Neuraminidase Inhibitor Consumed in Retail Stores
Figure 20. Global Neuraminidase Inhibitor Market: Retail Stores (2016-2021) & (K Units)
Figure 21. Neuraminidase Inhibitor Consumed in Others
Figure 22. Global Neuraminidase Inhibitor Market: Others (2016-2021) & (K Units)
Figure 23. Global Neuraminidase Inhibitor Sales Market Share by Application (2016-2021)
Figure 24. Global Neuraminidase Inhibitor Revenue Market Share by Application in 2020
Figure 25. Neuraminidase Inhibitor Revenue Market by Company in 2020 ($ Million)
Figure 26. Global Neuraminidase Inhibitor Revenue Market Share by Company in 2020
Figure 27. Global Neuraminidase Inhibitor Sales Market Share by Regions (2016-2021)
Figure 28. Global Neuraminidase Inhibitor Revenue Market Share by Region in 2020
Figure 29. Americas Neuraminidase Inhibitor Sales 2016-2021 (K Units)
Figure 30. Americas Neuraminidase Inhibitor Revenue 2016-2021 ($ Millions)
Figure 31. APAC Neuraminidase Inhibitor Sales 2016-2021 (K Units)
Figure 32. APAC Neuraminidase Inhibitor Revenue 2016-2021 ($ Millions)
Figure 33. Europe Neuraminidase Inhibitor Sales 2016-2021 (K Units)
Figure 34. Europe Neuraminidase Inhibitor Revenue 2016-2021 ($ Millions)
Figure 35. Middle East & Africa Neuraminidase Inhibitor Sales 2016-2021 (K Units)
Figure 36. Middle East & Africa Neuraminidase Inhibitor Revenue 2016-2021 ($ Millions)
Figure 37. Americas Neuraminidase Inhibitor Sales Market Share by Country in 2020
Figure 38. Americas Neuraminidase Inhibitor Revenue Market Share by Country in 2020
Figure 39. Americas Neuraminidase Inhibitor Sales Market Share by Type in 2020
Figure 40. Americas Neuraminidase Inhibitor Sales Market Share by Application in 2020
Figure 41. United States Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 42. Canada Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 43. Mexico Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 44. Brazil Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 45. APAC Neuraminidase Inhibitor Sales Market Share by Region in 2020
Figure 46. APAC Neuraminidase Inhibitor Revenue Market Share by Regions in 2020
Figure 47. APAC Neuraminidase Inhibitor Sales Market Share by Type in 2020
Figure 48. APAC Neuraminidase Inhibitor Sales Market Share by Application in 2020
Figure 49. China Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 50. Japan Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 51. Korea Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 52. Southeast Asia Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 53. India Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 54. Australia Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 55. Europe Neuraminidase Inhibitor Sales Market Share by Country in 2020
Figure 56. Europe Neuraminidase Inhibitor Revenue Market Share by Country in 2020
Figure 57. Europe Neuraminidase Inhibitor Sales Market Share by Type in 2020
Figure 58. Europe Neuraminidase Inhibitor Sales Market Share by Application in 2020
Figure 59. Germany Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 60. France Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 61. UK Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 62. Italy Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 63. Russia Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 64. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Country in 2020
Figure 65. Middle East & Africa Neuraminidase Inhibitor Revenue Market Share by Country in 2020
Figure 66. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Type in 2020
Figure 67. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Application in 2020
Figure 68. Egypt Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 69. South Africa Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 70. Israel Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 71. Turkey Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 72. GCC Country Neuraminidase Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 73. Channels of Distribution
Figure 74. Distributors Profiles
